{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_18636", "batch_size": 200, "batch_pos": 106, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 2, "answer": "no", "rationale": "The segment neutrally describes the scaling up of testing by a network.", "method": "llm_batch", "batch_id": "batch_2_16420", "batch_size": 200, "batch_pos": 69, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 3, "answer": "no", "rationale": "The segment discusses scaling up testing but lacks a moderate verb paired with significant scale or impact.", "method": "llm_batch", "batch_id": "batch_3_12332", "batch_size": 200, "batch_pos": 45, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_17652", "batch_size": 200, "batch_pos": 33, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 5, "answer": "no", "rationale": "The segment describes scaling up testing but lacks explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_18956", "batch_size": 200, "batch_pos": 30, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_10480", "batch_size": 200, "batch_pos": 5, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 7, "answer": "no", "rationale": "The segment describes testing activities but contains no bare negation.", "method": "llm_batch", "batch_id": "batch_7_13360", "batch_size": 200, "batch_pos": 1, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 8, "answer": "yes", "rationale": "Describes scaling up testing, a surveillance/capability measure, without explicit calming.", "method": "llm_batch", "batch_id": "batch_8_17300", "batch_size": 200, "batch_pos": 102, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
